A-Viral

A-Viral is a Danish biotechnology company focused on the development of a novel class of broad-spectrum antiviral drugs. The company's core technology is based on a "decoy" strategy that aims to block viral entry into host cells by mimicking the natural receptors used by viruses. Their lead candidate, AV-001, has demonstrated potential in treating a variety of respiratory viral infections, including influenza and COVID-19. By targeting conserved mechanisms of viral infection, A-Viral's platform seeks to provide effective treatments that are less susceptible to viral resistance. The company operates as a spin-out from the University of Copenhagen, leveraging deep academic expertise in virology and immunology.